Cytosorbents Corporation
CTSONASDAQHealthcare● Active
$0.42
+$0.01(+2.10%)
Market Cap$26555899
P/E Ratio—
52W High$1.39
52W Low$0.408
Cytosorbents Corporation (CTSO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CTSO · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $37.06M | $35.59M | $31.08M | $34.69M | $40.11M |
| Cost of Revenue | $10.57M | $10.71M | $9.13M | $13.96M | $11.05M |
| Gross Profit | $26.49M | $24.89M | $21.95M | $20.73M | $29.06M |
| Gross Margin %(computed) | 71.48% | 69.92% | 70.62% | 59.77% | 72.46% |
| Operating Expenses | |||||
| R&D Expenses | $5.08M | $7.61M | $15.59M | $15.12M | $16.38M |
| G&A Expenses | $0.00M | $0.00M | $37.87M | $2.21M | $38.48M |
| Total Operating Expenses | $40.73M | $41.34M | $53.90M | $52.25M | $51.81M |
| Operating Income | ($14.24M) | ($16.45M) | ($31.95M) | ($31.52M) | ($22.74M) |
| Operating Margin %(computed) | -38.42% | -46.22% | -102.78% | -90.87% | -56.71% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.13M | $0.03M |
| Interest Expense | $2.61M | $1.40M | $0.16M | $0.00M | $0.00M |
| Income Before Tax | ($8.60M) | ($22.41M) | ($30.06M) | ($33.91M) | ($25.29M) |
| Income Tax Expense | ($0.40M) | ($1.69M) | ($0.81M) | ($1.09M) | ($0.74M) |
| Net Income | ($8.20M) | ($20.72M) | ($29.25M) | ($32.81M) | ($24.56M) |
| Net Margin %(computed) | -22.12% | -58.21% | -94.09% | -94.59% | -61.23% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.13 | $-0.38 | $-0.65 | $-0.75 | $-0.57 |
| Wtd Avg Shares | 62.23M | 54.43M | 44.66M | 43.57M | 43.36M |
| EBITDA | ($4.36M) | ($19.27M) | ($27.88M) | ($30.00M) | ($21.62M) |
| EBITDA Margin %(computed) | -11.75% | -54.13% | -89.69% | -86.49% | -53.89% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Cytosorbents Corporation data
About Cytosorbents Corporation (CTSO) Income Statement
Cytosorbents Corporation (CTSO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CTSO reported revenue of $0.04B, gross profit of $0.03B (gross margin 71.48%), and net income of ($0.01B) — a net profit margin of -22.12%.
Frequently asked questions
CTSO · 4 questionsCytosorbents Corporation (CTSO) reported revenue of $0.04B for 2025, up 4.1% year-over-year.
CTSO revenueCTSO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09